Synovea DOI: A Cost-Effective Solution in Improving Skin
Hydration, Barrier Homeostasis & Epidermal Architecture.
•
•
•
It is a determinant of skin
appearance, mechanical
properties, barrier
function, and
metabolism.
% Hydration as a Function of Time after discontinuation of any product application
40
35
30
25
14
20
Days
15
10
2% DOI+ 2% Glycerol
Discontinuation of use
Water and barrier
homeostasis of the
epidermis is essential for
the normal function of
skin and for normal
stratum corneum (SC)
hydration.
Naturally Derived & Safe Starting Materials
Octanoic acid: Found naturally in coconuts, palm oil, breast
milk and goat milk; Used widely in skin care products as an
ester (Caprylic/capric triglycerides)
Isosorbide: Obtained by double dehydration of sorbitol, a
bio-feedstock; Used widely in skin and personal care
products as-is and as an ether (Dimethyl Isosorbide).
2% DOI
2% Glycerol
Placebo
5
In addition, it is
indispensable in
maintaining proper
water balance of the
body.
0
D+14
D+16
D+18
D+21
Results & Conclusion
 No product applied after 14 days
 Skin hydration level on 18th day
is superior to continuous 14-day
treatment with 2% Glycerol
Gene expression profile
Full thickness Mattek Epiderm tissue
Improves Water & Barrier Homeostasis
DNA microarray on human skin explant studies
Sytheon has designed
Synovea DOI, a patentpending compound, to
address these key issues.
Synovea® DOI stimulates Tight Junction genes & proteins

Placebo
Clinically proven to be very effective in
providing long-term skin hydration
Improves Epidermal & Dermo-Epidermal
Architecture
In addition, Synovea
DOI has been found to
improve dermoepidermal architecture
(flattened DEJ 
Undulating structure) as
revealed by the ex-vivo
study using human skin
explants


Proven by immuno-fluorescence &
histology
Significant stimulation of Aquaporin-3, ECadherin, Claudins & Desmosomes.
Organotypic skin tissue
Placebo
Synovea®DOI
 51 year old female
 Synovea DOI treatment for 7 days
 Stained with Toluidine blue in an
alkaline solution
Synovea DOI: A Cost-Effective Solution in Improving Skin
Hydration, Barrier Homeostasis & Epidermal Architecture.
cyberDERM
S12-31
Expert Grader Assessment of Tactile
Roughness
Skin dryness & roughness (legs)
(Scale: 0 = Normal—Smooth, soft, supple (yielding without wrinkling),
resilient to
8 = Severe Roughness—Rough feel, brittle; hard and inflexible upon
manipulation)
8
Chemical structure
Treatment = Synovea DOI Lot# P8537
S yno vea ® D OI : R = C 7H15
Control = No Treatment
Dioctanoyl Isosorbide
before treatment
Mean Score
6
4
2
Molecular Formula:
C22H38O6
CAS Number:
64896-70-4
INCI:
Isosorbide dicaprylate
Appearance:
Liquid
Miscibility:
A wide-range of
hydrophobic emollient
esters & solubilizers
Purity:
97% min
Patent Status:
US 0110117036A1
WO 2011059866A2
after treatment
0
Day 0
Day 14
Synovea® DOI stimulates E-Cadherin gene & protein
Day 17
Ex-Vivo E-Cadherin expression
Eye lid skin explant 51 year old female
DNA microarray & Ex-vivo on human skin explant studies
Gene expression profile
DNA microarray: Full thickness Mattek
Epiderm tissue
Placebo
SynoveaDOI
Summary Key benefits
 Suitable for sensitive skin
with high tolerance: No
skin irritation & No skin
sensitization (HRIPT; 5%
and 20% dilution in corn
oil); Elegant skin feel


 Suitable for vectorizing
cosmetic actives

Enhancing skin’s natural moisture retention
mechanisms by up-regulating AQP3 gene & protein;
Clinically proven.
Restoring barrier function by stimulating key tight
junction, desmosome & epidermal differentiation
genes & proteins.
Shaping the Epidermal architecture by stimulating
dermo-epidermal junction proteins
The information given and the recommendations made herein are based on our research and literature search and are believed to be accurate but no guarantee of their accuracy is
made. This information is intended to be helpful, but no warranty is expressed or implied as to the results obtained from use in the formulation, procedure or products suggested
herein. Neither is any permission or recommendation to practice any invention covered by patent either expressed or implied.
USA: Sytheon Ltd, 315 Wootton Street, Boonton, NJ 07005
Tel: +00(1)-973-988-1075; info@sytheonltd.com; www.sytheonltd.com
France: Sytheon SARL, 112 rue de Paris, 92100 Boulogne Billancourt
Tel +33-(0)1.41.10.81.82; sytheon@sytheonltd.com